NeOnc Technologies Reports Positive Phase 2a Brain Cancer Trial Data

Key Facts

In a move reflecting promising progress in the oncology biotech sector, NeOnc Technologies announced that its Phase 2a study of NEO100 for high-grade glioma successfully met its primary endpoint. According to reports, the trial demonstrated a six-month progression-free survival rate of 48.9%, significantly exceeding the pre-specified 20% benchmark. The study also reported a median overall survival of 26.09 months for patients with recurrent IDH1-mutant disease.

These clinical results strengthen the company's position in developing specialized treatments for rare and challenging brain cancers, as the study focused on a patient population currently lacking approved targeted therapies. Based on the available data, the 12-month survival rate stood at 60.9%, while 54.1% of patients remained alive at 24 months. The company now plans to request a Type B meeting with the U.S. FDA to discuss future regulatory steps based on this dataset.

Regarding market performance, price data for NTHI is currently unavailable as of August 12, 2026, making the stock's qualitative direction dependent on investor reaction to the clinical findings. Looking at the economic calendar, the market awaits the U.S. Initial Jobless Claims on August 6, 2026, which may influence general risk appetite within the small-cap biotech sector.